ArticleProceedings of the National Academy of Sciences of the United States of America2016
Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 96 citations in OpenAlex.
- Elevated 18:1 lysophosphatidylcholine contributes to neuropathic pain in peripheral nerve injury.Regional anesthesia and pain medicine · 2026Article
- Using an integrated omics approach to uncover the mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN).Communications medicine · 2026Review
- RNA-binding protein MBNL2 mitigates neuropathic pain after chemotherapy through destabilizing CCR2 expression in primary sensory neurons.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Article
- Proneurotrophin-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons.EMBO reports · 2025Article
- Neuroprotectin D1 and GPR37 protect against chemotherapy-induced peripheral neuropathy and the transition from acute to chronic pain.Pharmacological research · 2025Article
- The Octadecanoids: Synthesis and Bioactivity of 18-Carbon Oxygenated Fatty Acids in Mammals, Bacteria, and Fungi.Chemical reviews · 2025Review
- Evaluation and application analysis of animal models of PIPNP based on data mining.Open life sciences · 2025Review
- Article
- NT-3 contributes to chemotherapy-induced neuropathic pain through TrkC-mediated CCL2 elevation in DRG neurons.EMBO reports · 2024Article
- Cytochrome P450 26A1 Contributes to the Maintenance of Neuropathic Pain.Neuroscience bulletin · 2024Article
- Analysis of fatty acid-derived lipids in critically ill patients after cardiac surgery yields novel pathophysiologically relevant mediators with possible relevance for systemic inflammatory reactions.Frontiers in immunology · 2024Article
- Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake.Cells · 2023Article
- CYP1B1-derived epoxides modulate the TRPA1 channel in chronic pain.Acta pharmaceutica Sinica. B · 2023Article
- Potential novel therapeutic strategies for neuropathic pain.Frontiers in molecular neuroscience · 2023Review
- In Silico Drug Repurposing Framework Predicts Repaglinide, Agomelatine and Protokylol as TRPV1 Modulators with Analgesic Activity.Pharmaceutics · 2022Article
- The FKBP51 Inhibitor SAFit2 Restores the Pain-Relieving C16 Dihydroceramide after Nerve Injury.International journal of molecular sciences · 2022Article
- Excessive dietary linoleic acid promotes plasma accumulation of pronociceptive fatty acyl lipid mediators.Scientific reports · 2022Article
- Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer.Science translational medicine · 2022Article
- Systemic, Intrathecal, and Intracerebroventricular Antihyperalgesic Effects of the Calcium Channel Blocker CTK 01512-2 Toxin in Persistent Pain Models.Molecular neurobiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 2 countries.
Marco SisignanoInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany; Marco.Sisignano@med.uni-frankfurt.de.ORCID 0000-0002-7581-0951
Carlo AngioniInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Chul-Kyu ParkDepartment of Anesthesiology, Duke University Medical Center, Durham, NC 27710.
Sascha Meyer Dos SantosFraunhofer Institute for Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), D-60596 Frankfurt, Germany.
Holger JordanFraunhofer Institute for Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), D-60596 Frankfurt, Germany.
Maria KuzikovFraunhofer Institute for Molecular Biology and Applied Ecology-ScreeningPort, D-22525 Hamburg, Germany.
Di LiuDepartment of Anesthesiology, Duke University Medical Center, Durham, NC 27710.
Sebastian ZinnInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Stephan W HohmanInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Yannick SchreiberInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Béla ZimmerInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Mike SchmidtFraunhofer Institute for Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), D-60596 Frankfurt, Germany.
Ruirui LuInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Jing SuoInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Dong-Dong ZhangInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Stephan M G SchäferInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Martine HofmannFraunhofer Institute for Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), D-60596 Frankfurt, Germany.
Ajay S YekkiralaF. M. Kirby Neurobiology Center, Department of Neurobiology, Harvard Medical School, Children's Hospital Boston, Boston, MA 02115.
Natasja de BruinFraunhofer Institute for Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), D-60596 Frankfurt, Germany.
Michael J ParnhamFraunhofer Institute for Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), D-60596 Frankfurt, Germany.
Clifford J WoolfF. M. Kirby Neurobiology Center, Department of Neurobiology, Harvard Medical School, Children's Hospital Boston, Boston, MA 02115.
Ru-Rong JiDepartment of Anesthesiology, Duke University Medical Center, Durham, NC 27710.
Klaus ScholichInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Gerd GeisslingerInstitute of Clinical Pharmacology, Pharmazentrum Frankfurt/ZAFES (Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit), University Hospital, Goethe-University, D-60590 Frankfurt, Germany.
Goethe University Frankfurt · DEFraunhofer Institute for Molecular Biology and Applied Ecology · DEBoston Children's Hospital · USDuke University · USBrigham and Women's Hospital · US
Funding
ALTERED SENSIBILITY FOLLOWING PERIPHERAL NERVE DAMAGER01NS038253 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WOOLF, CLIFFORD J · 1999 to 2017
$8.2MResolvins, protectins, and chronic pain resolution.R01NS067686 · NINDS · DUKE UNIVERSITY · PI JI, RU-RONG, SERHAN, CHARLES NICHOLAS · 2009 to 2013
$2.8MNINDS NIH HHS R01 NS038253NINDS NIH HHS R01 NS067686
Abstract
Chemotherapy-induced peripheral neuropathic pain (CIPNP) is a severe dose- and therapy-limiting side effect of widely used cytostatics that is particularly difficult to treat. Here, we report increased expression of the cytochrome-P
Indexed as
Angiotensin II Type 1 Receptor BlockersAnimalsAntineoplastic Agents, PhytogenicBenzimidazolesBenzoatesCytochrome P-450 CYP2J2Cytochrome P-450 Enzyme SystemFemaleGanglia, SpinalGene Expression Regulation, EnzymologicHEK293 CellsHumansLinoleic AcidsMaleMice, Inbred C57BLMolecular Targeted Therapy9,10-epoxy-12-octadecenoic acidAngiotensin II Type 1 Receptor BlockersAntineoplastic Agents, PhytogenicBenzimidazolesBenzoatesCYP2J2 protein, humanCyp2j6 protein, mouseCytochrome P-450 CYP2J2Cytochrome P-450 Enzyme SystemLinoleic AcidsPaclitaxelTelmisartanchemotherapy-induced neuropathyneuropathic painoxidized lipidstelmisartanTRPV1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.